CNMD - CONMED Corporation
Canada Pension Plan Investment Board purchased a new position in CONMED Corporation (NYSE: CNMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,800 shares of the company's stock, valued at approximately $452,000. Other institutional investors also recently modified
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
California State Teachers Retirement System lifted its stake in shares of CONMED Corporation (NYSE: CNMD) by 38.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,340 shares of the company's stock after acquiring an additional 10,845 shares during the
Arrowstreet Capital Limited Partnership lifted its position in shares of CONMED Corporation (NYSE: CNMD) by 217.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 419,092 shares of the company's stock after buying an additional 287,150 shares during the quarter. Arrowstreet Capital
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.15 per share a year ago.
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company's previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons.
CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.
CONMED Corporation (NYSE: CNMD) today announced that its [url="]AirSeal Robotic Solution[/url] is now indicated for use with Intuitive's 8 mm hex cannulas us
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive's portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I.
Bessemer Group Inc. boosted its position in CONMED Corporation (NYSE: CNMD) by 46.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 116,429 shares of the company's stock after purchasing an additional 36,940 shares during the period. Bessemer Group Inc. owned about 0.39% of CONMED worth